Q-Linea logo

Accelerated Bookbuild Offering

SEK 301 million
Joint Bookrunner
;

Q-linea

Joint Bookrunner

Kempen & Co acted as Joint Bookrunner in Q-linea’s SEK 301m Capital Increase

Transaction highlights

  • Placement of 2.2m new shares at an offer price of SEK 137 per share generated gross proceeds of approximately SEK 301m
  • Q-linea intends to use the net proceeds to fund the final stages of the commercial launch of ASTar® together with its commercial partner, Thermo Fisher 
  • Furthermore, Q-linea plans to accelerate the development of ASTar® additional assays, including urine and isolates, as well as accelerate the development of the portable blood culturing technology product, which is expected to enter clinical studies in 2022
  • The capital increase was upsized during bookbuilding to 2.2m new shares from originally 2.0m new shares at launch, representing an increase of the company’s share capital by c. 8%
  • In 2021 year to date, Kempen & Co has already executed 14 transactions for European life sciences companies 

Company description

Q-linea is a diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. The company has signed a global partnership (excl. Sweden) with Thermo Fisher for the commercialisation of ASTar®. ASTar® recently achieved CE-IVD approval allowing Q-linea and Thermo Fisher to start commercialisation in Europe. In addition, the Q-linea recently initiated a 510(k) US clinical study for ASTar® with the goal of submitting a 510(k) application to the FDA during 2021.

Background Kempen & Co Life Sciences & Healthcare

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

  • Co-Manager in the USD 176 million Nasdaq Initial Public Offering by Achilles Therapeutics 
  • Joint Bookrunner in the €30 million Capital Increase by GenSight Biologics
  • Lead Manager in the USD 101 million Nasdaq Initial Public Offering by LAVA Therapeutics
  • Joint Bookrunner in the USD 120 million Nasdaq Initial Public Offering by European Biotech Acquisition Corp (EBAC)
  • Joint Bookrunner in the SEK 1.1 billion capital increase by Oncopeptides
  • Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
  • Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
  • Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
  • Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
  • Co-Manager in the USD 190 million Nasdaq Initial Public Offering by Pharvaris
  • Bookrunner in the USD 518 million US Public Offering by CureVac
  • Lead Manager in the USD 120 million US Public Offering by Merus 
  • Financial Adviser to DCprime in its merger with Immunicum 
  • Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
  • Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
  • Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
  • Lead Manager in the USD 95.1 million Nasdaq Initial Public Offering by Galecto
  • Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
  • Bookrunner in the USD 245 million Nasdaq Initial Public Offering by CureVac
  • Co-Manager in the USD 49.0 million US Public Offering by Centogene
  • Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
  • Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
  • Co-Manager in the USD 690 million US Public Offering by Ascendis Pharma
  • Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp, thereby becoming a Nasdaq listed company and securing USD 253 million
  • Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
  • Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
  • Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
  • Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
  • Co-Manager in the USD 862 million Global Offering by argenx
  • Joint Bookrunner in the SEK 1.41 billion Capital Increase by Oncopeptides

Contact

Kathrin Erfurth
Pieter van der Meijden

Transactions